文献速递妇科

细胞外囊泡假基因LGMNP1通过上调LGMN诱导M2样巨噬细胞极化并作为卵巢子宫内膜异位症复发的新型有前景预测生物标志物

The extracellular vesicular pseudogene LGMNP1 induces M2-like macrophage polarization by upregulating LGMN and serves as a novel promising predictive biomarker for ovarian endometriosis recurrence.
PubMed 文献 · Hum Reprod · 2022-01-01

本研究探讨卵巢子宫内膜异位症(EMs)中异位子宫内膜间质细胞来源的细胞外囊泡假基因LGMNP1(EV-LGMNP1)如何促进M2型巨噬细胞极化及其对复发的预测价值。体外实验显示EV-LGMNP1通过上调LGMN mRNA表达驱动巨噬细胞向M2样表型极化;临床回顾性队列(52例EMs患者和21例对照)中,复发患者血清EV-LGMNP1表达高于对照和无复发患者,基于血清EV-LGMNP1的列线图可预测复发。

要点

  • EV-LGMNP1通过上调LGMN mRNA表达促进巨噬细胞向M2样表型极化。
  • 复发EMs患者血清EV-LGMNP1表达高于对照和无复发EMs患者。
  • 血清EV-LGMNP1是预测EMs复发的有前景的非侵入性生物标志物。

核心结论

  • EV-LGMNP1在异位子宫内膜间质细胞和卵巢EMs患者血清中富集,通过上调LGMN表达诱导巨噬细胞M2样极化,是预测卵巢EMs复发的有前景生物标志物。

研究设计与样本

  • 体外研究使用2例卵巢EMs患者(经腹腔镜和组织学诊断)的异位子宫内膜样本分离的异位子宫内膜间质细胞。
  • 临床回顾性队列研究纳入52例卵巢EMs患者和21例对照,均有术前血清样本(2013-2017年),随访至复发或2018年12月31日。

主要发现

  • 体外实验表明EV/Ecto-ESCs驱动巨噬细胞向M2样表型极化。
  • LGMNP1通过上调LGMN mRNA表达水平参与EV/Ecto-ESC诱导的M2巨噬细胞极化。
  • 临床上,复发EMs患者血清EV-LGMNP1表达高于对照和无复发EMs患者。
  • 生存分析和新型列线图再次确认血清EV-LGMNP1是预测EMs复发的有前景且有意义的非侵入性生物标志物。

局限性

  • 体外实验仅使用2例卵巢子宫内膜异位症患者的样本,需要更大样本量。
  • 未来应研究从EMs和非EMs患者在位子宫内膜分离的子宫内膜间质细胞。
  • 体外实验应使用子宫内膜上皮细胞,并应进行进一步体内实验(如小鼠子宫内膜异位症模型)以研究EV/Ecto是否可诱导M2巨噬细胞极化。
  • 需要多中心、大样本数据验证预测列线图模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: How does ectopic endometrial stromal cell (Ecto-ESC)-derived extracellular vesicular Legumain pseudogene 1 (EV-LGMNP1), a newly identified pseudogene of Legumain (LGMN), contribute to M2-phenotype macrophage polarization, and does it predict recurrence in patients with ovarian endometriosis (EMs)? SUMMARY ANSWER: EV-LGMNP1, which is abundant in Ecto-ESCs and serum from ovarian EMs, can direct macrophages towards an M2 phenotype by upregulating LGMN expression and is a promising biomarker for predicting ovarian EMs recurrence. WHAT IS KNOWN ALREADY: Extracellular vesicles (EVs) can mediate cell-to-cell crosstalk to promote disease progression via cargo molecule transport. Recently, LGMNP1, a newly identified pseudogene of LGMN, has been reported to promote cancer progression by upregulating LGMN. LGMN is a well-studied protein that can induce M2-like polarization. STUDY DESIGN, SIZE, DURATION: An in vitro study was conducted with Ecto-ESCs isolated from ectopic endometrial samples, collected from two patients with ovarian EMs (diagnosed by laparoscopy and histological analysis). A clinical retrospective cohort study of 52 ovarian EMs patients and 21 controls with available preoperative serum samples was carried out (2013-2017). The follow-up period ended either at the time of recurrence or on 31 December 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: Ecto-ESC-derived EVs (EV/Ecto-ESCs) were characterized by nanoparticle tracking analysis, transmission electron microscopy and western blotting. EV internalization by THP-1 cells, which are the most widely used primary human macrophages model, was detected by fluorescence labelling. After EV treatment, THP-1 cell polarization was detected by quantitative real-time PCR (qRT-PCR) and western blot analyses of CD86 (M1-related marker) and CD206 (M2-related marker). LGMNP1 mRNA expression level in EVs from both primary ectopic endometrioc stromal cells and serum was examined using qRT-PCR. Additionally, the expression of LGMN, the downstream target gene of LGMNP1, in THP-1 cells was evaluated using qRT-PCR and western blotting. Kaplan-Meier and multivariate Cox regression analyses were applied to evaluate the independent predictive factors of EMs recurrence-free survival. A novel nomogram model based on serum EV-LGMNP1 was then formulated to predict EMs recurrence. MAIN RESULTS AND THE ROLE OF CHANCE: In vitro assays demonstrated that EV/Ecto-ESCs drove macrophages towards an M2-like phenotype. Moreover, LGMNP1 contributed to EV/Ecto-ESC-induced M2 macrophage polarization by upregulating LGMN mRNA expression levels. Clinically, serum EV-LGMNP1 was more highly expressed in recurrent EMs patients than in controls and EMs patients without recurrence. Survival analysis and our novel nomogram reconfirmed that serum EV-LGMNP1 was a novel promising and meaningful non-invasive biomarker for predicting EMs recurrence. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: In vitro experiments were only performed on samples from two patients with ovarian endometriosis, and a larger sample size is needed. ESCs isolated from the eutopic endometrium of EMs and non-EMs patients should be studied in the future. Additionally, in vitro experiments should be performed using endometrial epithelium cells and further in vivo experiments, such as using mice endometriotic models to investigate whether EV/Ecto could induce M2 macrophage polarization, should be conducted. Moreover, multicentre, large-sample data are needed to validate our predictive nomogram model. WIDER IMPLICATIONS OF THE FINDINGS: Our study provides novel insights into the mechanism of M2 polarization involved in ovarian EMs progression mediated by an 'EV-shuttled pseudogene LGMNP1' mode. In addition, serum EV-LGMNP1 may serve as a novel non-invasive biomarker for predicting recurrence, providing a new therapeutic target for ovarian EMs. STUDY FUNDING/COMPETING INTEREST(S): This project was supported by funding from the National Natural Science Foundation of China (81971361), the Natural Science Foundation of Shanghai Science and Technology (19ZR1406900), the Shanghai 'Rising Stars of Medical Talent' Youth Development Program (AB83030002019004), the Clinical Research Plan of SHDC (SHDC2020CR4087), the Shanghai Municipal Health Commission (202040498), the Research and Innovation Project of the Shanghai Municipal Education Commission (2019-01-07-00-07-E00050) and the Clinical Research Plan of SHDC (SHDC2020CR1045B). There are no competing interests to declare.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Sun SG, Guo JJ, Qu XY, et al. The extracellular vesicular pseudogene LGMNP1 induces M2-like macrophage polarization by upregulating LGMN and serves as a novel promising predictive biomarker for ovarian endometriosis recurrence. Hum Reprod. 2022. PMID: 34893848. doi:10.1093/humrep/deab266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。